Joint Statement Regarding COVID-19 Vaccine in Men Desiring Fertility from the Society for Male Reproduction and Urology (SMRU) and the Society for the Study of Male Reproduction (SSMR)
Jan 18, 2021
Published in: SMRU/SSMR Announcement
As of January 9, 2021, there are no data about the impact of the COVID-19 vaccine on male or female fertility. For women, the American College of Obstetrics and Gynecology (ACOG) recommends that pregnant and lactating women be offered the COVID-19 vaccine
. Similarly, the Society for Maternal Fetal Medicine has recommended that pregnant women have access to the currently approved Pfizer COVID-19 vaccine
. Finally, the American Society for Reproductive Medicine does not recommend withholding the vaccine from patients who are planning to conceive
, and emphasizes that ”patients undergoing fertility treatment and pregnant patients should be encouraged to receive vaccination based on eligibility criteria.“
For men, the SMRU and SSMR recommend that:
- The COVID-19 vaccine should not be withheld from men desiring fertility who meet criteria for vaccination.
- COVID-19 vaccines should be offered to men desiring fertility, similar to men not desiring fertility, when they meet criteria for vaccination.
It should be noted that about 16% of men in the Pfizer/BioNtech COVID-19 vaccine clinical trial experienced fever after the second dose. Fevers can cause temporary declines in sperm production. Thus, if a man experiences fever as the result of the COVID-19 vaccine, he may experience a temporary decline in sperm production, but that would be similar to or less than if the individual experienced fever from developing COVID-19 or for other reasons.
ASRM Announcements contain information of interest to members about ASRM and its affiliates, NIH, FDA, WHO, or CDC matters.